Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	55.33	46.7	101.94	180.37	132.83	81.93
Short-Term Investments	0	35.8	177.19	197.68	510.09	282.05
Cash & Cash Equivalents	55.33	82.5	279.13	378.05	642.92	363.97
Cash Growth	-73.25%	-70.44%	-26.16%	-41.20%	76.64%	-9.04%
Receivables	0.69	0.92	3.68	6.01	5.22	36.91
Other Current Assets	12.61	10.9	17.52	14.71	11.52	4.59
Total Current Assets	68.64	94.33	300.33	398.77	659.67	405.47
Property, Plant & Equipment	42.95	52.87	125.53	124.7	112.37	107.22
Long-Term Investments	0	0	29.85	88.17	50.53	21.83
Goodwill and Intangibles	0	0	88.28	93.46	100.93	92.43
Other Long-Term Assets	17.37	18.13	18.52	16.82	15.06	10.57
Total Long-Term Assets	60.33	70.99	262.18	323.15	278.88	232.04
Total Assets	128.96	165.32	562.51	721.92	938.55	637.52
Accounts Payable	15.47	15.26	22.42	9.76	12.55	6.67
Deferred Revenue	0	0	161.16	252.49	336.69	120.14
Other Current Liabilities	24.77	32.47	-71.86	-134.36	-205.7	-56.94
Total Current Liabilities	40.24	47.73	111.71	127.89	143.55	69.87
Long-Term Debt	30.82	33.52	38.99	44.06	38.4	41.19
Other Long-Term Liabilities	1.21	1.19	116.85	174.64	259.24	93.71
Total Long-Term Liabilities	32.02	34.7	155.84	218.69	297.64	134.91
Total Liabilities	72.26	82.43	267.55	346.58	441.18	204.78
Total Debt	30.82	33.52	38.99	44.06	38.4	41.19
Debt Growth	-18.26%	-14.03%	-11.51%	14.74%	-6.79%	48.77%
Retained Earnings	-1,455.47	-1,406.38	-1,148.55	-956.27	-777.98	-656.99
Comprehensive Income	-5.8	-4.6	-8.4	-3.99	5.42	-2.45
Shareholders' Equity	56.7	82.89	294.96	375.34	498.23	432.55
Net Cash / Debt	24.52	48.99	240.15	333.99	604.53	322.78
Net Cash / Debt Growth	-85.51%	-79.60%	-28.10%	-44.75%	87.29%	-13.33%
Net Cash Per Share	0.14	0.28	1.56	2.31	4.50	2.88
Working Capital	28.39	46.6	188.62	270.88	516.12	335.6
Book Value Per Share	0.31	0.47	1.91	2.60	3.71	3.86

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).